News | October 11, 2023
AstraZeneca’s Tagrisso to lead lung cancer small molecule market with over $7 billion sales by 2029, says GlobalData
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
Subscribe To Our Newsletter & Stay Updated
